Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PTCT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPTC Therapeutics issues $550M zero-coupon convertible notes, refinances 2026 debt
Filed June 18, 2026 · Period ending June 18, 2026 · ~1 min read
Key Changes
-
high
Issued $550M in 0% convertible senior notes due 2031, convertible at $107.48/share (9.3042 shares per $1,000 principal), representing potential dilution of ~5.1M shares if fully converted.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Used $328.8M of proceeds to repurchase $222M principal of existing 1.50% convertible notes due 2026, reducing outstanding balance to $55.5M and extending debt maturity while eliminating interest expense.
Item 8.01 — Other Events verify on EDGAR → -
medium
Notes are redeemable after June 2029 only if stock trades above $139.72 (130% of conversion price) for 20 of 30 trading days; holders can convert under specific conditions before March 2031.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Notes rank as unsecured senior obligations, equal with other unsecured debt but junior to secured debt and subsidiary obligations in bankruptcy scenarios.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
low
Notes sold to institutional buyers in private placement under Section 4(a)(2) and Rule 144A exemptions; underlying shares remain unregistered restricted securities.
Item 3.02 — Unregistered Sales of Equity Securities verify on EDGAR →
Summary
PTC Therapeutics executed a debt refinancing by issuing $550 million in zero-coupon convertible senior notes due 2031 and using proceeds to retire $222 million of its existing 1.50% convertible notes maturing in 2026. This transaction extends the company's debt maturity by five years while eliminating annual interest payments, improving near-term cash flow.
The new notes convert at $107.48 per share, representing approximately 5.1 million shares of potential dilution—a meaningful consideration for existing shareholders if conversion occurs. For retail investors, this is a balance sheet optimization move that reduces 2026 refinancing risk and lowers interest costs. The conversion price sits above current trading levels, suggesting management views the terms as favorable.
The company retains flexibility to use remaining proceeds for additional debt reduction or general corporate purposes. Watch whether PTC continues buying back the remaining $55.5 million of 2026 notes before maturity, which would further clean up the capital structure and signal confidence in liquidity management.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
PTC completed $550M convertible notes offering, using proceeds to repurchase $222M of existing 2026 notes and for general corporate purposes.
Added in current filing · verify on EDGAR →
On June 18, 2026, PTC Therapeutics, Inc. (the “Company”) completed its previously announced private offering of $550,000,000 aggregate principal amount of its 0.0% Convertible Senior Notes due 2031 (the “Notes”) and entered into an indenture with U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), governing the Notes (the “Indenture”).
PTC issued $550 million in zero-coupon convertible senior notes maturing in 2031. The notes convert at an initial rate of 9.3042 shares per $1,000 principal (conversion price approximately $107.48 per share). Holders can convert under specific conditions before March 2031, and anytime thereafter until maturity. The company can redeem the notes after June 2029 if the stock trades above 130% of conversion price for specified periods.
Added in current filing · verify on EDGAR →
The Company is using approximately $328.8 million of the net proceeds from the offering to repurchase for cash $222.0 million in aggregate principal amount of the Existing Convertible Notes pursuant to privately negotiated transactions with certain holders entered into concurrently with the pricing of the offering of the Notes. The remaining net proceeds from the offering will be used for general corporate purposes, which may include additional repurchases of the Existing Convertible Notes from time to time following the offering and the repayment or retirement of any remaining Existing Convertible Notes at maturity.
Of the approximately $535.5 million in net proceeds, PTC is using $328.8 million to repurchase $222 million principal amount of its existing 1.50% convertible notes due 2026. The remaining proceeds will fund general corporate purposes, potentially including further repurchases of the 2026 notes. This represents a debt refinancing transaction extending maturity from 2026 to 2031 while reducing interest costs from 1.50% to 0%.
Added in current filing · verify on EDGAR →
The initial conversion rate of the Notes is 9.3042 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $107.48 per share). The conversion rate will be subject to adjustment upon the occurrence of certain specified events but will not be adjusted for any accrued and unpaid special interest.
The notes convert at 9.3042 shares per $1,000 principal, equivalent to a $107.48 conversion price. This represents potential dilution of approximately 5.1 million shares if all notes convert (550,000 notes × 9.3042 shares). The conversion rate adjusts for certain corporate events but not for special interest. Upon conversion, PTC can choose to settle in cash, stock, or a combination.
Added in current filing · verify on EDGAR →
The Notes are the Company’s general unsecured, senior obligations and will rank senior in right of payment to any of its indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment with all of the Company’s existing and future unsecured indebtedness that is not so subordinated (including any of the Company’s outstanding 1.50% Convertible Senior Notes due 2026 (the “Existing Convertible Notes”)); effectively junior in right of payment to any of the Company’s senior, secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of the Company’s current or future subsidiaries.
The new notes are unsecured senior obligations ranking equal with existing convertible notes and other unsecured debt, but junior to any secured debt and subsidiary obligations. This means in a bankruptcy scenario, secured creditors and subsidiary creditors would be paid before these noteholders. The notes rank pari passu with the existing 2026 convertible notes being partially repurchased.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Item 3.02 — Unregistered Sales of Equity Securities filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Notes were sold to the Initial Purchasers in reliance on the exemption from the registration requirements provided by Section 4(a) (2) of the Securities Act for resale to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act.
The company sold convertible notes in a private placement to institutional buyers without SEC registration, using exemptions for qualified institutional buyers. The notes are convertible into common stock. The company does not plan to register the notes or underlying shares for resale, meaning they will remain restricted securities.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
After giving effect to such expected repurchases of the Existing Convertible Notes, the aggregate principal amount outstanding of Existing Convertible Notes would be $55.5 million.
Following the repurchase, only $55.5 million in principal amount of the existing convertible notes will remain outstanding. This substantially reduces the company's convertible debt obligations from the prior series.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 18, 2026 · How we verify